Most drug stocks have been out of favor in 2023.
Pfizer was down 43.4% as of the market close Monday, while
Johnson & Johnson is down 16.4%. Despite Eli Lilly’s monster 66.8% gain on the year, amid investor frenzy over its
weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.
Source: finance.yahoo.com
Related posts:
India’s Russian-Oil Buy: Red Flag or Red Herring?
We're entering a brutal new era for the housing market
Fed Heads Toward 75 Basis-Point Rate Hike With Officials Wary of Bigger Move
'Bond King' Jeffrey Gundlach says buy long-dated Treasurys, with prices set to rebound going into a ...
Fed issued its biggest rate hike in 22 years this week. 4 things to do with your money now that inte...